Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid

Pang Ning Teng, Brian L. Hood, Mai Sun, Rajiv Dhir, Thomas P. Conrads

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Renal cell carcinoma (RCC), the most common type of kidney cancer, currently has no biomarker of clinical utility. The present study utilized a mass spectrometry-based proteomics workflow for identifying differentially abundant proteins in RCC by harvesting shed and secreted proteins from the tumor microenvironment through sampling tissue interstitial fluid (TIF) from radical nephrectomies. Matched tumor and adjacent normal kidney (ANK) tissues were collected from 10 patients diagnosed with clear cell RCC. One-hundred thirty-eight proteins were identified with statistically significant differential abundances derived by spectral counting in tumor TIF when compared to ANK TIF. Among those proteins with elevated abundance in tumor TIF, nicotinamide n-methyltransferase (NNMT) and enolase 2 (ENO2) were verified by Western blot and selected reaction monitoring (SRM). The presence of ENO2 and thrombospondin-1 (TSP1) were verified as present and at elevated abundance in RCC patient serum samples as compared to a pooled standard control by enzyme-linked immunosorbent assay (ELISA), recapitulating the relative abundance increase in RCC as compared with ANK TIF.

Original languageEnglish
Pages (from-to)1333-1342
Number of pages10
JournalJournal of Proteome Research
Issue number3
StatePublished - 4 Mar 2011
Externally publishedYes


  • biomarker
  • cancer
  • proteomics
  • renal cell carcinoma
  • tissue interstitial fluid


Dive into the research topics of 'Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid'. Together they form a unique fingerprint.

Cite this